Phibro Animal Health (PAHC) reported $378.7 million in revenue for the quarter ended June 2025, representing a year-over-year increase of 38.6%. EPS of $0.57 for the same period compares to $0.41 a year ago.
The reported revenue represents a surprise of +4.86% over the Zacks Consensus Estimate of $361.15 million. With the consensus EPS estimate being $0.52, the EPS surprise was +9.62%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Phibro performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Net Sales by Region- United States: $201.99 million versus the two-analyst average estimate of $213.01 million. The reported number represents a year-over-year change of +31.4%.
- Net Sales by Region- Asia Pacific: $35.03 million versus the two-analyst average estimate of $23.07 million. The reported number represents a year-over-year change of +107.1%.
- Net Sales by Region- Europe, Middle East and Africa: $57.61 million versus $49.15 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +77.8% change.
- Net Sales by Region- Latin America and Canada: $84.07 million compared to the $72.87 million average estimate based on two analysts. The reported number represents a change of +19.8% year over year.
- Net Sales- Animal Health: $292.48 million compared to the $274.92 million average estimate based on three analysts. The reported number represents a change of +52.7% year over year.
- Net Sales- Mineral Nutrition: $64.15 million compared to the $66.4 million average estimate based on three analysts. The reported number represents a change of +3.3% year over year.
- Net Sales- Animal Health- Vaccines: $38.57 million versus the three-analyst average estimate of $35.23 million. The reported number represents a year-over-year change of +20.5%.
- Net Sales- Animal Health- MFAs and other: $206.53 million versus the three-analyst average estimate of $193.28 million. The reported number represents a year-over-year change of +77%.
- Net Sales- Animal Health- Nutritional specialties: $47.38 million versus the three-analyst average estimate of $46.42 million. The reported number represents a year-over-year change of +10.7%.
- Net Sales- Performance Products: $22.07 million versus the three-analyst average estimate of $19.83 million. The reported number represents a year-over-year change of +12.6%.
- Adjusted EBITDA- Animal Health: $60.58 million versus $59.83 million estimated by two analysts on average.
- Adjusted EBITDA- Corporate: $-19.25 million versus $-21.43 million estimated by two analysts on average.
View all Key Company Metrics for Phibro here>>>
Shares of Phibro have returned +16.5% over the past month versus the Zacks S&P 500 composite's +1.3% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Phibro Animal Health Corporation (PAHC): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
